IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

12 -

Applicant:

Gerd GEISSLINGER et al.

Title:

USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES

FOR PRODUCING

MEDICAMENTS WITH AN

INHIBITING EFFECT ON BETA-GLUCURONIDASE IN HUMAN

TISSUE

Appl. No.:

09/980,824

Filing Date:

12/07/2001

Examiner:

B. Kwon

Art Unit:

1614

AMENDMENT TRANSMITTAL

Mail Stop NON-FEE AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

- [] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a previous assertion of Small Entity status.
- [] Assertion of Small Entity status is enclosed.
- [] The fee required for additional claims is calculated below:

	Claims As Amended		Previously Paid For	,	Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	11		20	=	0	х	\$18.00	==	\$0.00
Independents:	3		3	=	0	x	\$84.00	=	\$0.00
First presentat Claims:	ion of any	Mul	tiple Depe	nde	ent	+	\$280.00	=	\$0.00

\$0.00

CLAIMS FEE TOTAL: =

	CEANIO I E.	D TOTAL.	\$0.00
	pplicant hereby petitions for an extension of time total number of months checked below:	under 37 C.F.R.	§1.136(a) for the
	Extension for response filed within the first month:	\$110.00	\$0.00
[]		\$110.00	\$0.00
[]	Extension for response filed within the second month:	\$410.00	\$0.00
	Extension for response filed within the third		
[]	month:	\$930.00	\$0.00
	Extension for response filed within the fourth		
[]	month:	\$1,450.00	\$0.00
	Extension for response filed within the fifth		•
[]	month:	\$1,970.00	\$0.00
	EXTENSION FE	E TOTAL:	\$0.00
r 2	Statutory Disclaimer Fee under 37 C.F.R.	011000	40.00
[]	1.20(d):	\$110.00	\$0.00
	CLAIMS, EXTENSION AND DISCLAI	MER FEE TOTAL:	\$0.00
[]	Small Entity Fees Apply (subtract ½	_	\$0.00
LJ		TAL FEE:	\$0.00
	lease charge Deposit Account No. 19-0741 in the a fthis transmittal is enclosed.	mount of \$0.00.	A duplicate cop
] A	check in the amount of \$0.00 is enclosed.		
equired of Depositions because the deposition of	the Commissioner is hereby authorized to charge are regarding this application under 37 C.F.R. §§ 1.16-t. Account No. 19-0741. Should no proper payment in the wrong amount, unsigned, post-dated, otherely missing, the Commissioner is authorized to charge	1.17, or credit and the enclosed he erwise improper	ny overpayment, crewith, as by a or informal or

Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date

FOLEY & LARDNER

Washington Harbour 3000 K Street, N.W., Suite 500

Washington, D.C. 20007-5143

Telephone: Facsimile:

(202) 295-4767 (202) 672-5399 Ву

Steven M. Reid, Ph.D. Representative for Applicant

Registration No. 54,393

SEP 1 2 2003

Atty. Dkt. No. 016946-0252 Appln. Ser. No. 097930,824

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Àpplicant:

Gerd GEISSLINGER et al.

Title:

USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES FOR

PRODUCING MEDICAMENTS WITH AN INHIBITING EFFECT ON

BETA-GLUCURONIDASE IN HUMAN TISSUE

Appl. No.:

09/980,824

Filing Date:

12/07/2001

Examiner:

B. Kwon

Art Unit:

1614

AMENDMENT AND REPLY UNDER 37 CFR 1.111

Mail Stop NON-FEE AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

This communication is responsive to the Non-Final Office Action dated June 12, 2003, concerning the captioned patent application. A response is due by September 12, 2003, thereby making this submission timely filed.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 4 of this document.

Please amend the application as follows: